Evaluation of the Detrimental Effects of some Antiepileptic Drugs on the Height and Weight of Children with Epilepsy
Keywords:Growth, weight, percentile, Carbamazepine, Valproic acid
Growth is a multifactorial process influenced by genetic, nutritional, hormonal, psychosocial and other factors including the general health of a child. Epilepsy defined as a chronic condition characterized by recurrent clinical events or epileptic seizures, which occur in the absence of a metabolic or toxic disease the drugs that use in the treatment of this condition can affect patients growth due to their mechanisms of action. This study aimed to evaluate the effect of some antiepileptic drugs on growth (height and weight) in children with epilepsy. This work involved 51 newly diagnosed children with a different form of epilepsy (Generalized, absent and partial). Patients divided into three groups according to the treatment (group one patients on Carbamazepine monotherapy with dose mean 13.3 ± 4.8 mg/Kg, group two patients on Valproic acid monotherapy with a dose of 14.4± 3.3 mg/kg and the last group involve patient on combined therapy Carbamazepine 10.8±5.8 plus 19.7± 8.8 of Valproic acid. Patients age range from 5-11 years, with an Initial BMI range of 12-20. The results of this work showed that Carbamazepine monotherapy caused no significant affected on both BMI values after 6 and 12 months of treatment (p>0.05). Valproic acid monotherapy significantly elevated BMI after 6 and 12 months of treatment (p>0.01). Combined therapy showed no significate effect on BMI. The patient’s centile height significantly elevated after 6 and 12 months of Valproic acid (p<0.01) compared to the normal growth according to the growth chart. While both Carbamazepine and combined therapy showed no significant change in comparison to the normal growth according to the growth chart (p>0.05). In conclusion, children with epilepsy who use antiepileptic drugs need restricted monitor policy for their growth, especially those on Valproic acid.
(US) NRC, (US) I of M. Influences on Children’s Health. 2004;
Pediatric Endocrinology E-Book - Mark A. Sperling - Google Books.
Rosenbloom AL. Physiology of growth. Vol. 65, Annales Nestle. 2008. p. 97–108.
Emons J, Chagin AS, Sävendahl L, Karperien M, Wit JM. Mechanisms of growth plate maturation and epiphyseal fusion. Vol. 75, Hormone Research in Paediatrics. Karger Publishers; 2011. p. 383–91.
Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC Growth Charts for the United States: Methods and Development. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. 2002.
Beghi E. The Epidemiology of Epilepsy. Neuroepidemiology. 2020 Mar;54(2):185–91.
Epileptic State - an overview | ScienceDirect Topics.
Pressler RM, Cilio MR, Mizrahi EM, Solomon |, Moshé L, Nunes ML, et al. The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia. 2021;00:1–14.
Pohlmann-Eden B, Beghi E, Camfield C, Camfield P. The first seizure and its management in adults and children. BMJ Br Med J. 2006 Feb;332(7537):339.
Goldenberg MM. Overview of Drugs Used For Epilepsy and Seizures: Etiology, Diagnosis, and Treatment. Pharm Ther. 2010 Jul;35(7):392.
Brigo F, Igwe SC. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2017 Feb;2017(2).
De Onis M, Onyango A, Borghi E, Siyam A, Pinol A, Garza C, et al. Enrolment and baseline characteristics in the WHO Multicentre Growth Reference Study. Acta Paediatr Int J Paediatr. 2006;95(SUPPL. 450):7–15.
INALOO S, SAKI F, PAKTINAT M, KATIBEH P, NEMATI H, OMRANI GR. Evaluation of The Metabolic Syndrome Criteria And Body Composition in Ambulatory Children with Epilepsy UsingSodium Valproate and Carbamazepine In Southern Iran: A Case-Control Study. Iran J Child Neurol. 2020;14(3):47.
Saruwatari J, Ishitsu T, Seo T, Shimomasuda M, Okada Y, Goto S, et al. The clinical impact of cytochrome p450 polymorphisms on anti-epileptic drug therapy. Epilepsy and Seizure. 2010 Apr;3(1):34–50.
HS L, SY W, DM S, CC W, SJ C, HC F. The impact of the use of antiepileptic drugs on the growth of children. BMC Pediatr. 2013 Dec;13(1).
Valsamis HA, Arora SK, Labban B, McFarlane SI. Antiepileptic drugs and bone metabolism. Nutr Metab. 2006;3:1–11.
Copyright (c) 2022 Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.